These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 25687055)
21. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro]. Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538 [TBL] [Abstract][Full Text] [Related]
22. [The effect of arsenic trioxide (As2O3) combined with BSO on K562/ADM cell and its mechanisms]. Wang T; Ma LM; Zhang HP; Wang HW; Yang LH; Qiao ZH Zhonghua Xue Ye Xue Za Zhi; 2007 Jul; 28(7):438-43. PubMed ID: 18072624 [TBL] [Abstract][Full Text] [Related]
23. [Correlation between mTOR signaling transduction pathway and arsenic trioxide response]. Jiang F; Liu ZG Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):54-6. PubMed ID: 20137118 [TBL] [Abstract][Full Text] [Related]
24. [Protein kinase C inhibitor Gö6976 sensitizes arsenic trioxide-induced cell apoptosis in chronic myeloid leukemic cells]. Wu XF; Chen ZC; Liu ZP; You Y; Li WM; Zou P Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):100-3. PubMed ID: 15748445 [TBL] [Abstract][Full Text] [Related]
25. [Synergistic lethal effect of combined treatment of arsenic trioxide and aclacinomycin on human acute myeloid leukemia cell line KG-1a]. Ye YB; Xu XJ; Chen YH; Zhang MW; Qiu DF; Guo ZW; He HQ Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):256-262. PubMed ID: 28550664 [No Abstract] [Full Text] [Related]
26. Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide. Gao SM; Chen C; Wu J; Tan Y; Yu K; Xing CY; Ye A; Yin L; Jiang L Biochem Biophys Res Commun; 2010 Dec; 403(2):203-8. PubMed ID: 21056550 [TBL] [Abstract][Full Text] [Related]
27. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway. Wei YL; Liang Y; Xu L; Zhao XY Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306 [TBL] [Abstract][Full Text] [Related]
28. [Mechanism underlying 2-methoxyestradiol inducing apoptosis of K562 cells]. Zhang XY; Zhan R; Huang HB; Yang T Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):340-4. PubMed ID: 19379563 [TBL] [Abstract][Full Text] [Related]
29. [Effect of A Novel Emodin Derivative on Chronic Myelogenous Leukemia K562 Cells and Imatinib-resistant K562/G01 Cells]. Li BJ; Liu TB; Wang WF; Lin MH; Hu JD Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):1-7. PubMed ID: 26913384 [TBL] [Abstract][Full Text] [Related]
30. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms. Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418 [TBL] [Abstract][Full Text] [Related]
31. [Effect of up-regulated expression of tumor suppressor gene p14(ARF) on apoptosis of chronic myeloid leukemia cells]. Bai YS; Liu J; Liu XH; Dai EY; Sun BT; Lu ZX Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):512-5. PubMed ID: 23827110 [TBL] [Abstract][Full Text] [Related]
32. [Synergism of As2S2 and STI 571 in inducing apoptosis of K562 cells]. Li JE; Sun GL; Wu YL; Wu WL Zhonghua Xue Ye Xue Za Zhi; 2003 Nov; 24(11):580-3. PubMed ID: 14720443 [TBL] [Abstract][Full Text] [Related]
33. [Apoptosis of KBM5R cell line with T315I point mutation induced by arsenic trioxide]. Li XF; Li JH; Wang CH; Wang XL; Liu QJ; Xu W; Jia B; Qiu L; Ma J Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):643-7. PubMed ID: 21729541 [TBL] [Abstract][Full Text] [Related]
34. Effects of arsenic trioxide administration styles on leukocytosis. Zhou J; Meng R; Sui XH; Meng L; Yang BF Chin Med Sci J; 2006 Jun; 21(2):111-4. PubMed ID: 16845799 [TBL] [Abstract][Full Text] [Related]
35. Overexpression of transglutaminase 2 accelerates the erythroid differentiation of human chronic myelogenous leukemia K562 cell line through PI3K/Akt signaling pathway. Kang SK; Lee JY; Chung TW; Kim CH FEBS Lett; 2004 Nov; 577(3):361-6. PubMed ID: 15556610 [TBL] [Abstract][Full Text] [Related]
36. [Effects of arsenic trioxide combined with bortezomib on proliferation and apoptosis of K562 cells and their mechanism]. Wu HY; Wang SM; Huang JQ; Hao LM; Li XM; Wei LY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1361-4. PubMed ID: 23257433 [TBL] [Abstract][Full Text] [Related]
37. Accumulation of gamma-globin mRNA and induction of irreversible erythroid differentiation after treatment of CML cell line K562 with new doxorubicin derivatives. Szulawska A; Arkusinska J; Czyz M Biochem Pharmacol; 2007 Jan; 73(2):175-84. PubMed ID: 17097070 [TBL] [Abstract][Full Text] [Related]
38. Identifying arsenic trioxide (ATO) functions in leukemia cells by using time series gene expression profiles. Yang H; Lin S; Cui J Gene; 2014 Feb; 535(2):312-7. PubMed ID: 24262935 [TBL] [Abstract][Full Text] [Related]
39. [Arsenic trioxide combined with buthionine sulfoximine enhances apoptosis in multidrug-resistant human leukemia K562/ADM cells in vitro]. Wang T; Ma LM; Zhang HP; Wang HW; Yang LH; Qiao ZH Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):188-91. PubMed ID: 18756933 [TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration. Kim JH; Kim JH; Yu YS; Kim DH; Kim CJ; Kim KW Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1819-23. PubMed ID: 19060284 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]